A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [31] Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18–70 years
    Fatemeh Gholami
    Ramin Hamidi Farahani
    Ahmad Karimi Rahjerdi
    Mohammadreza Ahi
    Ali Sheidaei
    Kimiya Gohari
    Zahra Rahimi
    Akram Ansarifar
    Pouria Basiri
    Milad Moradi
    Arash Jahangiri
    Kosar Naderi
    Soheil Ghasemi
    Pezhman Khatami
    Mohsen Honari
    Samane Khodaverdloo
    Mohammad Shooshtari
    Hajar Mehr Azin
    Sohrab Moradi
    Batool Shafaghi
    Hossein Allahyari
    Arina Monazah
    Ali Khodaei Poor
    Zahra Taghva
    Hooman Bakhshande
    Mohammad Karimi Nia
    Masoud Solaymani Dodaran
    Mohsen Forooghizade
    BMC Infectious Diseases, 23
  • [32] Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial
    Hu, Weijun
    Liu, Xiaoyu
    Lu, Xi
    Zhang, Dan
    Liu, Shuo
    Gu, Xianjin
    Liu, Dan
    Sun, Jianwen
    Zhou, Tiantian
    Li, Xinge
    Gao, Yongjun
    Zhao, Yanwei
    Cui, Guoliang
    Zhang, Shaobai
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [33] A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results
    Schoergenhofer, Christian
    Gelbenegger, Georg
    Hasanacevic, Dzenita
    Schoener, Lea
    Steiner, Margarete M.
    Firbas, Christa
    Buchtele, Nina
    Derhaschnig, Ulla
    Tanzmann, Andreas
    Model, Nina
    Larcher-Senn, Julian
    Drost, Manuel
    Eibl, Martha M.
    Roetzer, Andreas
    Jilma, Bernd
    ECLINICALMEDICINE, 2024, 67
  • [34] Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
    Dicko, Alassane
    Ouedraogo, Jean-Bosco
    Zongo, Issaka
    Sagara, Issaka
    Cairns, Matthew
    Yerbanga, Rakiswende Serge
    Issiaka, Djibrilla
    Zoungrana, Charles
    Sidibe, Youssoufa
    Tapily, Amadou
    Nikiema, Frederic
    Sompougdou, Frederic
    Sanogo, Koualy
    Kaya, Mahamadou
    Yalcouye, Hama
    Dicko, Oumar Mohamed
    Diarra, Modibo
    Diarra, Kalifa
    Thera, Ismaila
    Haro, Alassane
    Sienou, Abdoul Aziz
    Traore, Seydou
    Mahamar, Almahamoudou
    Dolo, Amagana
    Kuepfer, Irene
    Snell, Paul
    Grant, Jane
    Webster, Jayne
    Milligan, Paul
    Lee, Cynthia
    Ockenhouse, Christian
    Ofori-Anyinam, Opokua
    Tinto, Halidou
    Djimde, Abdoulaye
    Chandramohan, Daniel
    Greenwood, Brian
    LANCET INFECTIOUS DISEASES, 2024, 24 (01): : 75 - 86
  • [35] Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study
    Vesikari, Timo
    Saez-Llorens, Xavier
    Blazevic, Vezna
    Lopez, Pio
    Lopez, Eduardo
    Masuda, Taisei
    Mendelman, Paul M.
    Liu, Mengya
    Sherwood, James
    Baehner, Frank
    Borkowski, Astrid
    VACCINE, 2022, 40 (26) : 3588 - 3596
  • [36] Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Huang, Tao
    Wang, Danni
    Zhang, Li
    Deng, Yao
    Chang, Xianyun
    Liu, Yafei
    Li, Weiqi
    Zhang, Siyuan
    Huang, Weijin
    Tan, Wenjie
    Gao, Lidong
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (12) : 1136 - 1142
  • [37] The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial
    Xie, Zhiqiang
    Li, Jiangjiao
    Wang, Xue
    Huang, Lili
    Gou, Jinbo
    Zhang, Wei
    Huang, Haitao
    You, Wangyang
    Wang, Feiyu
    Li, Xiaolong
    Zhang, Jinming
    Han, Qiang
    Ma, Xiaomin
    Wang, Yanxia
    VACCINES, 2024, 12 (12)
  • [38] Safety and efficacy of venoplasty in MS A randomized, double-blind, sham-controlled phase II trial
    Traboulsee, Anthony L.
    Machan, Lindsay
    Girard, J. Marc
    Raymond, Jean
    Vosoughi, Reza
    Hardy, Brian W.
    Emond, Francois
    Gariepy, Jean-Luc
    Bone, Jeffrey N.
    Siskin, Gary
    Klass, Darren
    Isserow, Saul
    Illes, Judy
    Sadovnick, A. Dessa
    Li, David K.
    NEUROLOGY, 2018, 91 (18) : E1660 - E1668
  • [39] A randomized, double-blind, controlled trial to evaluate the safety and immunogenicity of killed oral cholera vaccine (Shanchol®) in healthy individuals in Ethiopia
    Desai, S. N.
    Akalu, Z.
    Teshome, S.
    Yamuah, L.
    Kim, D. R.
    Yang, J. S.
    Teferi, M.
    Hussein, J.
    Wierzba, T. F.
    Aseffa, A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 431 - 432
  • [40] Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind,-controlled, 3 trial
    Hannawi, Suad
    Wu, Xiao-Hong
    Villalobos, Ralph Elvi
    Burhan, Erlina
    Borra, Ma. Dovie Lallaine
    Gupta, Rakesh Kumar
    Aquitania, Grace P.
    Ang, Blake Warren C.
    Zabat, Gelza Mae A.
    Roa, Camilo C.
    Zoleta-De Jesus, Loreta
    Dan-Dan, Yu
    Wang, Meng
    Wu, Yan
    Song, Wen-Jie
    Ying, Bo
    Qin, Cheng-Feng
    MED, 2024, 5 (10):